Literature DB >> 29371236

CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling.

Sung Wook Park1, Shawna D Persaud1, Stanislas Ogokeh1, Tatyana A Meyers2, DeWayne Townsend2, Li-Na Wei3.   

Abstract

Excessive and/or persistent activation of calcium-calmodulin protein kinase II (CaMKII) is detrimental in acute and chronic cardiac injury. However, intrinsic regulators of CaMKII activity are poorly understood. We find that cellular retinoic acid-binding protein 1 (CRABP1) directly interacts with CaMKII and uncover a functional role for CRABP1 in regulating CaMKII activation. We generated Crabp1-null mice (CKO) in C57BL/6J background for pathophysiological studies. CKO mice develop hypertrophy as adults, exhibiting significant left ventricular dilation with reduced ejection fraction at the baseline cardiac function. Interestingly, CKO mice have elevated basal CaMKII phosphorylation at T287, and phosphorylation on its substrate phospholamban (PLN) at T17. Acute isoproterenol (ISO) challenge (80 mg/kg two doses in 1 day) causes more severe apoptosis and necrosis in CKO hearts, and treatment with a CaMKII inhibitor KN-93 protects CKO mice from this injury. Chronic (30 mg/kg/day) ISO challenge also significantly increases hypertrophy and fibrosis in CKO mice as compared to WT. In wild-type mice, CRABP1 expression is increased in early stages of ISO challenge and eventually reduces to the basal level. Mechanistically, CRABP1 directly inhibits CaMKII by competing with calmodulin (CaM) for CaMKII interaction. This study demonstrates increased susceptibility of CKO mice to ISO-induced acute and chronic cardiac injury due to, at least in part, elevated CaMKII activity. Deleting Crabp1 results in reduced baseline cardiac function and aggravated damage challenged with acute and persistent β-adrenergic stimulation. This is the first report of a physiological role of CRABP1 as an endogenous regulator of CaMKII, which protects the heart from ISO-induced damage.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  CRABP1; CaMKII; cardiac remodeling; heart failure

Mesh:

Substances:

Year:  2018        PMID: 29371236      PMCID: PMC5815894          DOI: 10.1530/JOE-17-0613

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  43 in total

1.  Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stress.

Authors:  Jana Strakova; Jon D Dean; Katharine M Sharpe; Tatyana A Meyers; Guy L Odom; DeWayne Townsend
Journal:  J Mol Cell Cardiol       Date:  2014-08-24       Impact factor: 5.000

2.  CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury.

Authors:  Martin Vila-Petroff; Margarita A Salas; Matilde Said; Carlos A Valverde; Luciana Sapia; Enrique Portiansky; Roger J Hajjar; Evangelia G Kranias; Cecilia Mundiña-Weilenmann; Alicia Mattiazzi
Journal:  Cardiovasc Res       Date:  2006-12-15       Impact factor: 10.787

Review 3.  Chasing cardiac physiology and pathology down the CaMKII cascade.

Authors:  Alicia Mattiazzi; Rosana A Bassani; Ariel L Escobar; Julieta Palomeque; Carlos A Valverde; Martín Vila Petroff; Donald M Bers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

4.  The cellular retinoic acid binding protein I is dispensable.

Authors:  P Gorry; T Lufkin; A Dierich; C Rochette-Egly; D Décimo; P Dollé; M Mark; B Durand; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

5.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.

Authors:  Ting Zhang; Yan Zhang; Mingyao Cui; Li Jin; Yimei Wang; Fengxiang Lv; Yuli Liu; Wen Zheng; Haibao Shang; Jun Zhang; Mao Zhang; Hongkun Wu; Jiaojiao Guo; Xiuqin Zhang; Xinli Hu; Chun-Mei Cao; Rui-Ping Xiao
Journal:  Nat Med       Date:  2016-01-04       Impact factor: 53.440

Review 6.  Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol.

Authors:  Zuzana Nichtova; Marta Novotova; Eva Kralova; Tatiana Stankovicova
Journal:  Gen Physiol Biophys       Date:  2012-06       Impact factor: 1.512

7.  Calmodulin mediates differential sensitivity of CaMKII and calcineurin to local Ca2+ in cardiac myocytes.

Authors:  Jeffrey J Saucerman; Donald M Bers
Journal:  Biophys J       Date:  2008-08-08       Impact factor: 4.033

8.  Inducible cardiomyocyte-specific deletion of CaM kinase II protects from pressure overload-induced heart failure.

Authors:  Michael M Kreusser; Lorenz H Lehmann; Nora Wolf; Stanislav Keranov; Andreas Jungmann; Hermann-Josef Gröne; Oliver J Müller; Hugo A Katus; Johannes Backs
Journal:  Basic Res Cardiol       Date:  2016-09-28       Impact factor: 17.165

Review 9.  The Diagnosis and Evaluation of Dilated Cardiomyopathy.

Authors:  Alan G Japp; Ankur Gulati; Stuart A Cook; Martin R Cowie; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2016-06-28       Impact factor: 24.094

10.  All-Trans Retinoic Acid Ameliorates Myocardial Ischemia/Reperfusion Injury by Reducing Cardiomyocyte Apoptosis.

Authors:  Zhengbin Zhu; Jinzhou Zhu; Xiaoran Zhao; Ke Yang; Lin Lu; Fengru Zhang; Weifeng Shen; Ruiyan Zhang
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

View more
  13 in total

1.  Retinoid metabolism and functions mediated by retinoid binding-proteins.

Authors:  Joseph L Napoli; Hong Sik Yoo
Journal:  Methods Enzymol       Date:  2020-04-01       Impact factor: 1.600

Review 2.  Research progress on the role of CaMKII in heart disease.

Authors:  Shi-Jun Jiang; Wei Wang
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  Multi-omic Analysis of Non-human Primate Heart after Partial-body Radiation with Minimal Bone Marrow Sparing.

Authors:  Stephanie Zalesak-Kravec; Weiliang Huang; Pengcheng Wang; Jianshi Yu; Tian Liu; Amy E Defnet; Alexander R Moise; Ann M Farese; Thomas J MacVittie; Maureen A Kane
Journal:  Health Phys       Date:  2021-10-01       Impact factor: 2.922

4.  Role of cellular retinol-binding protein, type 1 and retinoid homeostasis in the adult mouse heart: A multi-omic approach.

Authors:  Stephanie Zalesak-Kravec; Weiliang Huang; Jace W Jones; Jianshi Yu; Jenna Alloush; Amy E Defnet; Alexander R Moise; Maureen A Kane
Journal:  FASEB J       Date:  2022-04       Impact factor: 5.834

Review 5.  Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.

Authors:  William S Blaner
Journal:  Pharmacol Ther       Date:  2019-01-29       Impact factor: 12.310

6.  Regulation of exosome secretion by cellular retinoic acid binding protein 1 contributes to systemic anti-inflammation.

Authors:  Yi-Wei Lin; Jennifer Nhieu; Chin-Wen Wei; Yu-Lung Lin; Hiroyuki Kagechika; Li-Na Wei
Journal:  Cell Commun Signal       Date:  2021-06-30       Impact factor: 5.712

7.  A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1.

Authors:  Sung Wook Park; Jennifer Nhieu; Shawna D Persaud; Michelle C Miller; Youlin Xia; Yi-Wei Lin; Yu-Lung Lin; Hiroyuki Kagechika; Kevin H Mayo; Li-Na Wei
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

8.  Cellular retinoic acid binding protein 1 protects mice from high-fat diet-induced obesity by decreasing adipocyte hypertrophy.

Authors:  Yi-Wei Lin; Sung Wook Park; Yu-Lung Lin; Frank H Burton; Li-Na Wei
Journal:  Int J Obes (Lond)       Date:  2019-06-04       Impact factor: 5.095

9.  Crabp1 Modulates HPA Axis Homeostasis and Anxiety-like Behaviors by Altering FKBP5 Expression.

Authors:  Yu-Lung Lin; Chin-Wen Wei; Thomas A Lerdall; Jennifer Nhieu; Li-Na Wei
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

10.  Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection.

Authors:  Meili Lu; Bin Leng; Xin He; Zhen Zhang; Hongxin Wang; Futian Tang
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.